CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 77,545	$ 25,218
Short-term investments	541,771	708,737
Accounts receivable	10,006	22,492
Inventory	16,969	15,801
Other current assets	19,245	23,333
Total current assets	665,536	795,581
Long-term investments	8,928	64,828
Property, plant and equipment, net	39,792	60,510
Operating lease right-of-use assets	68,996	117,025
Goodwill	76,501	76,501
Other assets	2,234	2,744
Total assets	861,987	1,117,189
Current liabilities:
Accounts payable	12,346	9,747
Accrued compensation	30,323	15,735
Accrued clinical trial expenses	29,234	26,809
Other accrued expenses	13,035	15,468
Operating lease liabilities, current portion	20,047	17,441
Total current liabilities	104,985	85,200
Operating lease liabilities, less current portion	119,415	125,736
Development derivative liability	0	27,726
Liabilities related to the sales of future royalties, net	176,775	195,427
Other long-term liabilities	2,080	3,592
Total liabilities	403,255	437,681
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated or outstanding at June 30, 2022 or December 31, 2021, respectively	0	0
Common stock, $0.0001 par value; 300,000 shares authorized; 187,405 shares and 185,468 shares outstanding at June 30, 2022 and December 31, 2021, respectively	19	19
Capital in excess of par value	3,549,360	3,516,641
Accumulated other comprehensive loss	(8,191)	(4,157)
Accumulated deficit	(3,082,456)	(2,832,995)
Total stockholders’ equity	458,732	679,508
Total liabilities and stockholders’ equity	$ 861,987	$ 1,117,189